Don’t Miss This Bullish Run on OWC Pharmaceutical Research Corp (OTCMKTS:OWCP)

0
324
GWPH

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) shares rose 36.57% on Friday to $0.915 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.95. The company has a market cap of $128.82 million at 135.31 million shares outstanding.

OWC Pharmaceutical Research Corp is a medical cannabis research and development company. As such, it is engaged in the research and development of cannabis-based medical products for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications.

The company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. It was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device, and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder migraines and a delivery system.

Last week, OWC Pharmaceutical Corp announced that it would be presenting at the Wall Street Conference, which will be held at the Hilton Doubletree Hotel and Conference Center in Deerfield Beach, Boca Raton, Florida, on Wednesday, March 1, 2017. This premiere conference in the venture capital arena and small-cap marketplace includes industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, who attend to discuss significant trends in the financial markets.

The Wall Street Conference is one of the leading conferences for small-cap investors and OWC is excited to be a part of it. OWC continues to make significant progress in the research and development of cannabis-centric medical treatments, specifically with our psoriasis cream, which is being readied for the U.S. and European markets.  We are focused on having our products on the shelves in the MMJ states this year. I am very much looking forward to discussing the Company with conference attendees,” remarked Ziv Turner, OWC Pharmaceutical Corp’s VP Business development and Managing Director of One World Cannabis.

Member of the company’s Advisory Board, Jeffrey Friedland, is a featured speaker at the Conference and is expected to discuss the opportunities for public company investments in the cannabis sector, and the positive impact that Israeli science and companies are having on the U.S. and Canadian cannabis markets. He is also CEO of Intiva Inc., which was an early-stage investor in OWC, and the author of Marijuana: The Worlds Most Misunderstood Plant.

The legal cannabis market has expanded considerably over the past two years, generating significant and growing investor interest. However, there are only a handful of publicly-traded companies focused on cannabinoid-based, pharmaceutical development and a true scientific approach to product development. I intend to discuss what I see as the publicly-traded cannabis opportunities at the Conference,” Friedland noted.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.